CTIS2023-503186-35-00进行中（未招募）1 期
AP-recAP-HPP-01-01
AM-Pharma B.V.0 个研究点目标入组 12 人开始时间: 2023年1月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects: Study Part A follows a randomized, cross-over design to compare three dose levels of inhaled LASAG to one dose level of intravenously administered LASAG and Study Part B follows a single group design to investigate a XXXXX LASAG inhalation solution.CTIS2022-503037-63-00Aspiair GmbH28
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart FailureCTIS2022-500347-20-00Anacardio AB116
进行中（未招募）
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergyCTIS2023-505783-11-00Alk-Abello A/S12
进行中（未招募）
1 期
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasarge Granular Lymphocytic Leukemia or Cytotoxic LymphomasMedDRA version: 20.0Level: LLTClassification code: 10029430Term: NK-cell leukemia Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065862Term: T-cell large granular lymphocytic leukemia Class: 10029104CTIS2023-503550-13-00Dren Bio Inc.116
进行中（未招募）
1 期
A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktailHereditary angioedemaCTIS2024-514713-35-0014